Skin patch T-cell Covid vaccine to be trialled in Switzerland
The new vaccine will be administered as a tiny skin patch bristling with micro-needles that release the shot within seconds.
Keystone / Alexandra Wey
A British biotech firm is set to start clinical trials in Switzerland of a skin patch vaccine against Covid-19 that uses T-cells and could offer longer-lasting immunity than existing vaccines.
This content was published on
2 minutes
The Guardian/swissinfo/sb
Español
es
Suiza someterá a prueba vacuna COVID en parche cutáneo
Emergex announcedExternal link on Monday that it had received the green light from the Swiss drugs regulator to carry out initial human trials in Lausanne, starting January 3, 2022.
The company’s easy-to-administer skin patch vaccine primes T-cells – a group of immune cells that can target and destroy virus-infected cells – to remove infected cells from the body quickly after infection, thus preventing viral replication and disease.
Robin Cohen, Emergex’s chief commercial officer, told The GuardianExternal link newspaper: “This is the first time a regulator has approved a Covid vaccine to go into clinical trials whose sole purpose is to generate a targeted T-cell response in the absence of an antibody response and those T-cells look for infected cells and kill them.”
Current Covid-19 vaccines mainly generate an antibody response that wanes over time, which means people need booster shots to maintain protection against the virus. The Emergex vaccine works differently, by killing infected cells quickly. This means it could offer longer-lasting immunity – possibly for decades – and could also be better at fighting virus mutations, said Cohen.
The trial will be conducted by Blaise Genton, a professor at the University of Lausanne’s centre for primary care and public health. He said: “This exciting new scientific approach to developing a vaccine against Sars-CoV-2 addresses the need to generate a T-cell response to elicit long-term immunity.”
In all, 26 people will receive a high and a low dose of its experimental Covid-19 vaccine. Interim results from the trial are expected in June.
More
More
Swiss Politics
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Lindt & Sprüngli reportedly considering shifting Easter bunny production to US
This content was published on
Swiss chocolate manufacturer Lindt & Sprüngli could relocate the production of its gold-wrapped Easter bunnies to the US in order to circumvent the import tariffs imposed by the Trump administration.
Swiss petition launched against curbing 30km/h speed limit
This content was published on
The Traffic Club of Switzerland (TCS) has submitted a petition to the Federal Chancellery, challenging the 30km/h speed limit on local roads.
Swiss government backs abolishing imputed rental value
This content was published on
The abolition of the imputed rental value in federal tax is intended to reduce incentives for high private debt and simplify the tax system. On Friday, Finance Minister Karin Keller-Sutter spoke on behalf of the Federal Council in favour of Parliament's proposal.
This content was published on
After a strong start to the year, the Swiss economy has slowed considerably. In the second quarter, gross domestic product (GDP) rose by just 0.1 per cent on an adjusted basis compared to the previous quarter.
This content was published on
The Ticino cantonal criminal court in Lugano has found a priest guilty of multiple sexual assault and sexual offences with minors. The man was sentenced to a conditional 18-month prison term.
Swiss disappointed by failed plastics agreement in Geneva
This content was published on
Switzerland will not get its Geneva agreement against plastic pollution. Chief negotiator Felix Wertli spoke on Friday morning of his delegation's disappointment.
While Switzerland struggles to vaccinate, Portugal is already finished
This content was published on
Nowhere are more people vaccinated against Covid-19 than in Portugal, where 98% of over 25-year-olds have had both doses.
Vaccine alternative has limited impact on Covid campaign
This content was published on
The offer of a non-mRNA Covid vaccine in Switzerland has failed to speed up the government’s vaccination campaign, experts say.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.